- Home
- About Us
- Doctors
- Specialties
- Bariatric Surgery
- Bone Marrow Transplant
- Cancer
- Cardiology
- Cardiovascular And Thoracic Surgery
- Critical Care Medicine
- Dental Surgery
- Dermatology & Cosmetology
- Diabetic Foot Care
- Ear, Nose & Throat
- Endocrinology
- Fetal Medicines
- Gastroenterology
- General Medicine
- General Surgery
- HPB & Gastrointestinal Surgery
- Interventional Radiology
- IVF
- Kidney Transplant
- Laparoscopic Surgery
- Liver Transplant
- Medical And Hemato Oncology
- Neurology
- Neuro & Spine Surgery
- Nephrology And Dialysis
- Nuclear Medicine
- Orthopedic
- Ophthalmology
- Obstetrics And Gynecology
- Pathology Laboratory
- Pediatric
- Peripheral Vascular And Endovascular Surgery
- Physiotherapy and Rehabilitation
- Plastic Reconstruction
- Plastic & Cosmetic Surgery
- Pulmonary Medicine
- Radiation Oncology
- Radiology
- Robotic Surgery
- Surgical Oncology
- Urology
- Facilities
- Patient Area
- Testimonials
- Media
- Contact Us
Myelodysplastic Syndrome
Bloodstream Wellness: Illuminate Your Path to MDS Health
Welcome to Universal Hospital’s Myelodysplastic Syndrome (MDS) Care, where we are dedicated to providing comprehensive care for individuals affected by MDS. MDS is a group of disorders characterized by dysfunctional blood cell production in the bone marrow.
What is Myelodysplastic Syndrome?
Myelodysplastic Syndrome (MDS) refers to a group of disorders characterized by abnormal development and dysfunction of blood-forming cells in the bone marrow. In MDS, the bone marrow fails to produce sufficient healthy blood cells, leading to low blood cell counts. This condition can progress to acute myeloid leukemia (AML) in some cases.
Subtypes of MDS: MDS is categorized into various subtypes based on the type of blood cells affected, the severity of symptoms, and other factors.
Risk Factors:
- Age: MDS is more common in older adults, and the risk increases with age.
- Gender: MDS is slightly more prevalent in males than females.
- Chemotherapy or Radiation Therapy: Previous exposure to certain cancer treatments can increase the risk.
- Exposure to Certain Chemicals: Prolonged exposure to certain chemicals like benzene.
- Certain Genetic Syndromes: Inherited conditions such as Fanconi anemia.
Symptoms:
- Fatigue: Due to low red blood cell count (anemia).
- Frequent Infections: Resulting from low white blood cell count.
- Easy Bruising or Bleeding: Due to low platelet count.
- Shortness of Breath: Caused by anemia.
- Pale Skin: Another symptom of anemia.
Staging:
MDS is not traditionally staged like some cancers, but the International Prognostic Scoring System (IPSS) and Revised IPSS (IPSS-R) are commonly used to assess prognosis.
International Prognostic Scoring System (IPSS):
- Low Risk: Includes low-grade MDS subtypes with a longer survival expectancy.
- Intermediate-1 Risk: Represents an intermediate stage.
- Intermediate-2 Risk: Indicates a higher risk of progression to acute myeloid leukemia (AML).
- High Risk: Includes MDS with a high likelihood of progression to AML.
Revised International Prognostic Scoring System (IPSS-R):
- Further refines risk assessment by considering additional factors.
- Categories include Very Low, Low, Intermediate, High, and Very High risk.
Diagnosis:
- Blood Tests: Complete blood count (CBC) to assess levels of red and white blood cells and platelets.
- Bone Marrow Biopsy: Examination of a sample of bone marrow to evaluate cell morphology and quantity.
- Cytogenetic Testing: Analysis of the chromosomes in bone marrow cells.
Treatment:
Treatment approaches for MDS depend on the subtype, severity, and the individual’s overall health. Common interventions include:
- Supportive Care: Addressing symptoms and complications, such as blood transfusions and growth factors.
- Hematopoietic Stem Cell Transplantation (HSCT): A potentially curative option for some individuals.
- Chemotherapy: Low-dose chemotherapy to manage symptoms and improve blood cell counts.
- Immunosuppressive Therapy: To modulate the immune system’s response in certain cases.
Prevention:
There are no specific measures for preventing MDS. Avoiding known risk factors, such as exposure to certain chemicals, may reduce the risk in some cases.
Prognosis:
Prognosis in MDS varies widely based on factors such as the specific subtype, the severity of cytopenias (low blood cell counts), and the individual’s overall health. Some cases may remain stable for years, while others may progress to acute leukemia.
Screening:
Routine screening for MDS is not typically performed in the general population. Diagnosis often occurs when symptoms prompt further investigation.
Why Choose Universal Hospital for MDS Care:
- Expert Hematology Team: Our MDS Care Center is staffed by a team of hematologists, oncologists, and supportive care professionals with extensive experience in the diagnosis and treatment of myelodysplastic syndrome.
- Cutting-Edge Treatments: Universal Hospital offers a range of advanced treatments, including targeted therapies, chemotherapy, supportive care, and participation in clinical trials, ensuring patients have access to the latest advancements in MDS care.
- Holistic Patient Care: We prioritize individualized care plans that consider not only the medical aspects of MDS but also the overall well-being of our patients, providing support and resources beyond the treatment room.
